2020
Prognostic and Predictive Biomarkers in Oligometastatic Disease.
Barnum KJ, Weiss SA. Prognostic and Predictive Biomarkers in Oligometastatic Disease. The Cancer Journal 2020, 26: 100-107. PMID: 32205533, PMCID: PMC9208067, DOI: 10.1097/ppo.0000000000000438.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCirculating Tumor DNAClinical Decision-MakingDisease-Free SurvivalHumansMicroRNAsMutationNeoplasmsNeoplastic Cells, CirculatingPatient SelectionPrognosisProgression-Free SurvivalRadiofrequency AblationRadiosurgeryRisk AssessmentSurvival RateConceptsLocal therapyOligometastatic diseaseSystemic therapyPredictive biomarkersCurative-intent local therapyAdvanced disease stateCancer-related deathSurvival benefitPatient candidatesMetastatic lesionsPatient selectionPoor prognosisAblative treatmentClinical definitionTumor biologyTherapyOligometastasesDisease statesDiseasePatientsLocal interventionsBiomarkersPolymetastasesPrognosisLesions
2015
Sensitivity of plasma BRAFmutant and NRASmutant cell‐free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non‐RECIST disease progression
Chang GA, Tadepalli JS, Shao Y, Zhang Y, Weiss S, Robinson E, Spittle C, Furtado M, Shelton DN, Karlin-Neumann G, Pavlick A, Osman I, Polsky D. Sensitivity of plasma BRAFmutant and NRASmutant cell‐free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non‐RECIST disease progression. Molecular Oncology 2015, 10: 157-165. PMID: 26440707, PMCID: PMC4695284, DOI: 10.1016/j.molonc.2015.09.005.Peer-Reviewed Original ResearchConceptsNew brain metastasesDisease progressionTreatment initiationBrain metastasesDisease activityCtDNA levelsMetastatic melanomaProgression eventsRECIST scoresUseful blood-based biomarkerImmune checkpoint blockadeDisease progression eventsBRAF inhibitor therapyBlood-based biomarkersCell-free DNA assaysCheckpoint blockadeMetastatic diseaseInhibitor therapyTreatment courseLDH levelsPatient managementUseful biomarkerPatientsDroplet digital PCR assaysProgressionPhosphorylation of eIF2α triggered by mTORC1 inhibition and PP6C activation is required for autophagy and is aberrant in PP6C-mutated melanoma
Wengrod J, Wang D, Weiss S, Zhong H, Osman I, Gardner LB. Phosphorylation of eIF2α triggered by mTORC1 inhibition and PP6C activation is required for autophagy and is aberrant in PP6C-mutated melanoma. Science Signaling 2015, 8: ra27. PMID: 25759478, PMCID: PMC4580977, DOI: 10.1126/scisignal.aaa0899.Peer-Reviewed Original ResearchMeSH KeywordsAmino AcidsAutophagyCell Line, TumorClustered Regularly Interspaced Short Palindromic RepeatsEnzyme ActivationEukaryotic Initiation Factor-2Gene Knock-In TechniquesHumansImmunoblottingImmunohistochemistryImmunoprecipitationMass SpectrometryMechanistic Target of Rapamycin Complex 1MelanomaMicroscopy, FluorescenceMultiprotein ComplexesMutationPhosphoprotein PhosphatasesPhosphorylationProtein Serine-Threonine KinasesSirolimusTOR Serine-Threonine KinasesTunicamycinConceptsKinase complex mTORC1Amino acid-sensing systemsProtein phosphatase 6Activation of GCN2Amino acid deprivationEukaryotic initiation factorPharmacological inhibitionWild-type alleleKinase GCN2Human melanoma samplesGCN2 activationRegulatory subunitCatalytic subunitInitiation factorsPathways downstreamPP6cGCN2MTORC1PhosphorylationAutophagyMutantsMelanoma samplesSubunitsMutationsActivation